<DOC>
	<DOCNO>NCT00002536</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Giving chemotherapy drug surgery may shrink tumor remove surgery . PURPOSE : Randomized phase III trial compare surgery without chemotherapy treat patient stage IB cervical cancer .</brief_summary>
	<brief_title>Surgery With Without Chemotherapy Treating Patients With Stage IB Cervical Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare disease free survival , overall survival , local control patient bulky stage IB carcinoma cervix treat radical hysterectomy pelvic para-aortic lymphadenectomy without neoadjuvant vincristine cisplatin . II . Compare adverse effect radical hysterectomy pelvic para-aortic lymphadenectomy without neoadjuvant vincristine cisplatin patient . OUTLINE : This randomize study . Patients randomize 1 2 treatment arm . Arm I : Surgery . All patient undergo intra-abdominal retroperitoneal exploratory laparotomy . Patients without metastasis also undergo radical hysterectomy pelvic para-aortic lymphadenectomy . Beginning 2-4 week surgery , patient 1 positive lymph node positive surgical margin radical hysterectomy specimen receive adjunctive radiotherapy 5 day week 4-6 week . Patients histologically confirm metastasis undergo radical hysterectomy pelvic para-aortic lymphadenectomy , receive radiotherapy 5 day week 6-8 week begin 2-4 week laparotomy . Patients undergo radiotherapy also receive cisplatin IV 1 hour day radiotherapy administered 6 dos cisplatin . Arm II : Patients receive vincristine IV bolus immediately follow cisplatin IV 1 hour day 1 , 11 , 21 . Courses repeat every 21 day 3 course absence disease progression unacceptable toxicity . Beginning approximately 4 week last dos neoadjuvant vincristine cisplatin , patient receive surgery , radiotherapy , cisplatin Arm I . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 170-340 patient accrue study approximately 4.5 year .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Previously untreated , histologically proven invasive carcinoma cervix Eligible histology : Squamous Adenocarcinoma Adenosquamous Eligible stage : Bulky stage IB , i.e . : Exophytic lesion 4 cm great diameter OR Cervix expand 4 cm great presume clinically result cancer No extension beyond cervix clinically IVP CT contrast PATIENT CHARACTERISTICS : Age : Not specify Performance status : GOG 02 Hematopoietic : WBC least 3,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 time normal AST great 3 time normal Alkaline phosphatase great 3 time normal Renal : Creatinine great 2.0 mg/dL Other : No septicemia severe infection No concurrent malignancy within past 5 year except curatively treat nonmelanomatous skin cancer prior malignancy therapy contraindicate current protocol therapy Suitability radical hysterectomy lymphadenectomy require PRIOR CONCURRENT THERAPY : No prior therapy cervical cancer No prior pelvic irradiation</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>stage IB cervical cancer</keyword>
</DOC>